1 |
SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,71(3):209-249. doi:10.3322/caac.21660
doi: 10.3322/caac.21660
|
2 |
VILLANUEVA A, HERNANDEZ-GEA V, LLOVET J M. Medical therapies for hepatocellular carcinoma: a critical view of the evidence[J]. Nat Rev Gastroenterol Hepatol, 2013,10(1):34-42. doi:10.1038/nrgastro.2012.199
doi: 10.1038/nrgastro.2012.199
|
3 |
ANWANWAN D, SINGH S K, SINGH S, et al. Challenges in liver cancer and possible treatment approaches[J]. Biochim Biophys Acta Rev Cancer, 2020,1873(1):188314. doi:10.1016/j.bbcan.2019.188314
doi: 10.1016/j.bbcan.2019.188314
|
4 |
COSENS D J, MANNING A. Abnormal electroretinogram from a Drosophila mutant[J]. Nature, 1969,224(5216):285-287. doi:10.1038/224285a0
doi: 10.1038/224285a0
|
5 |
NILIUS B, OWSIANIK G. The transient receptor potential family of ion channels[J]. Genome Biol, 2011,12(3):218. doi:10.1186/gb-2011-12-3-218
doi: 10.1186/gb-2011-12-3-218
|
6 |
SHAPOVALOV G, RITAINE A, SKRYMA R, et al. Role of TRP ion channels in cancer and tumorigenesis[J]. Semin Immunopathol, 2016,38(3):357-369. doi:10.1007/s00281-015-0525-1
doi: 10.1007/s00281-015-0525-1
|
7 |
BOUSTANY C EL, BIDAUX G, ENFISSI A, et al. Capacitative calcium entry and transient receptor potential canonical 6 expression control human hepatoma cell proliferation[J]. Hepatology, 2008,47(6):2068-2077. doi:10.1002/hep.22263
doi: 10.1002/hep.22263
|
8 |
STOKLOSA P, BORGSTROM A, KAPPEL S, et al. TRP channels in digestive tract cancers[J]. Int J Mol Sci, 2020,21:1877. doi:10.3390/ijms21051877
doi: 10.3390/ijms21051877
|
9 |
MIAO X, LIU G, XU X, et al. High expression of vanilloid receptor-1 is associated with better prognosis of patients with hepatocellular carcinoma[J]. Cancer Genet Cytogenet, 2008,186(1):25-32. doi:10.1016/j.cancergencyto.2008.05.011
doi: 10.1016/j.cancergencyto.2008.05.011
|
10 |
LIU G, XIE C, SUN F, et al. Clinical significance of transient receptor potential vanilloid 2 expression in human hepatocellular carcinoma[J]. Cancer Genet Cytogenet, 2010, 197(1):54-59. doi:10.1016/j.cancergencyto.2009.08.007
doi: 10.1016/j.cancergencyto.2009.08.007
|
11 |
KOH H H, CHOI S, PARK C K, et al. Down-regulation of TRPV6 Is Associated With Adverse Prognosis in Hepatocellular Carcinoma Treated With Curative Resection[J]. Cancer Genomics Proteomics, 2022,19(2):259-269. doi:10.21873/cgp.20318
doi: 10.21873/cgp.20318
|
12 |
WANG W, LIU P, ZHANG Y, et al. Expression and functions of transient receptor potential channels in liver diseases[J]. Acta Pharm Sin B, 2023,13(2):445-459. doi:10.1016/j.apsb.2022.09.005
doi: 10.1016/j.apsb.2022.09.005
|
13 |
XU J, YANG Y, XIE R, et al. The NCX1/TRPC6 Complex Mediates TGFβ-Driven Migration and Invasion of Human Hepatocellular Carcinoma Cells[J]. Cancer Res, 2018,78(10) :2564-2576. doi:10.1158/0008-5472.can-17-2061
doi: 10.1158/0008-5472.can-17-2061
|
14 |
ZHU S, YE H, XU X, et al. Involvement of TRPC7-AS1 Expression in Hepatitis B Virus-Related Hepatocellular Carcinoma[J]. J Oncol, 2021,2021:8114327. doi:10.1155/2021/8114327
doi: 10.1155/2021/8114327
|
15 |
FANG Y, LIU G, XIE C, et al. Pharmacological inhibition of TRPV4 channel suppresses malignant biological behavior of hepatocellular carcinoma via modulation of ERK signaling pathway[J]. Biomed Pharmacother, 2018,101:910-919. doi:10.1016/j.biopha.2018.03.014
doi: 10.1016/j.biopha.2018.03.014
|
16 |
ROEHLEN N, CROUCHET E, BAUMERT T F. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives[J]. Cells, 2020, 9(4):875. doi:10.3390/cells9040875
doi: 10.3390/cells9040875
|
17 |
LIU Q, LEI X, CAO Z, et al. TRPM8 deficiency attenuates liver fibrosis through S100A9-HNF4α signaling[J]. Cell Biosci, 2022,12(1):58. doi:10.1186/s13578-022-00789-4
doi: 10.1186/s13578-022-00789-4
|
18 |
SELLI C, ERAC Y, KOSOVA B, et al. Silencing of TRPC1 regulates store-operated calcium entry and proliferation in Huh7 hepatocellular carcinoma cells[J]. Biomed Pharmacother, 2015,71:194-200. doi:10.1016/j.biopha.2015.02.024
doi: 10.1016/j.biopha.2015.02.024
|
19 |
ANAND P, FILIPENKO P, HUAMAN J, et al. Selective Inhibition of Liver Cancer Cells Using Venom Peptide[J]. Mar Drugs, 2019,17(10):587. doi:10.3390/md17100587
doi: 10.3390/md17100587
|
20 |
SELLI C, PEARCE D A, SIMS A H, et al. Differential expression of storeoperated calcium-and proliferation-related genes in hepatocellular carcinoma cells following TRPC1 ion channel silencing[J]. Mol Cell Biochem, 2016, 420(1/2):129-140. doi:10.1007/s11010-016-2776-0
doi: 10.1007/s11010-016-2776-0
|
21 |
CHEN Y, YU Y, SUN S, et al. Bradykinin promotes migration and invasion of hepatocellular carcinoma cells through TRPM7 and MMP2[J]. Exp Cell Res, 2016, 349(1):68-76. doi:10.1016/j.yexcr.2016.09.022
doi: 10.1016/j.yexcr.2016.09.022
|
22 |
HUANG S P, CHEN J C, WU C C, et al. Capsaicin-induced apoptosis in human hepatoma HepG2 cells[J]. Anticancer Res, 2009, 29(1):165-174.
|
23 |
HAN L, DI C X, MAO A H, et al. Mechanism of Capsazepine inducing apoptosis of human hepatocellular carcinoma cell line HepG2[J]. Chin J Cancer Prev Trea, 2015,22(10):764-769.
|
24 |
CHEN W T, LIN G B, LIN S H, et al. Static magnetic field enhances the anticancer efficacy of capsaicin on HepG2 cells via capsaicin receptor TRPV1[J]. PLoS One, 2018,13(1):e0191078. doi:10.1371/journal.pone.0191078
doi: 10.1371/journal.pone.0191078
|
25 |
ZHANG N, BAI S H, ZHANG F H, et al. Molecular markers and mechanisms for stemness maintenance of liver cancer stem cells: a review[J]. Chin J Biotech, 2021, 37(8): 2719-2736.
|
26 |
HU Z, CAO X, FANG Y, et al. Transient receptor potential vanilloid-type 2 targeting on stemness in liver cancer[J]. Biomed Pharmacother, 2018, 105:697-706. doi:10.1016/j.biopha.2018.06.029
doi: 10.1016/j.biopha.2018.06.029
|
27 |
HUANG A, YANG X R, CHUNG W Y, et al. Targeted therapy for hepatocellular carcinoma[J]. Signal Transduct Target Ther, 2020,5(1):146. doi:10.1038/s41392-020-00264-x
doi: 10.1038/s41392-020-00264-x
|
28 |
BORT A, SPÍNOLA E, RODRÍGUEZ-HENCHE N, et al. Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation[J]. Oncotarget,2017,8(50):87684-87698. doi:10.18632/oncotarget.21196
doi: 10.18632/oncotarget.21196
|
29 |
THOPPIL R J, ADAPALA R K, CAPPELLI H C, et al. TRPV4 channel activation selectively inhibits tumor endothelial cell proliferation[J]. Sci Rep, 2015,5:14257. doi:10.1038/srep14257
doi: 10.1038/srep14257
|
30 |
ADAPALA R K, THOPPIL R J, GHOSH K, et al. Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy[J]. Oncogene, 2016,35(3):314-322. doi:10.1038/onc.2015.83
doi: 10.1038/onc.2015.83
|